Advertisement

Journal of Endocrinological Investigation

, Volume 42, Issue 11, pp 1361–1363 | Cite as

Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis

  • C. PascucciEmail author
  • R. V. De Biase
  • D. Savi
  • S. Quattrucci
  • L. Gnessi
  • C. Lubrano
  • A. Lenzi
Rapid Communication
  • 74 Downloads

Abstract

Introduction

A new class of drugs in the treatment of cystic fibrosis (CF) includes two agents: lumacaftor, which corrects CFTR channel protein, and ivacaftor, which increases CFTR channel activity. In our previous study we recruited 50 stable adults with CF and 16 of them showed growth hormone deficit (GHD): 7 patients severe and 9 patients partial GHD.

Material and methods

We decided to re-evaluate ten patients with the GHRH + arginine test of whom only five were treated with lumacaftor/ivacaftor.

Results

All CF patients in therapy with lumacaftor/ivacaftor showed a marked improvement in GHD. Two patients moved from a severe GHD to a normal response to the GH/IGF-1 axis test, and three patients who had partial GHD moved to normal response.

Conclusion

The pituitary gland may be damaged by CF disease and could benefit of the action of correcting drugs.

Keywords

Growth hormone Insulin-like growth factor-1 Cystic fibrosis Lumacaftor Ivacaftor Adult patients 

Notes

Acknowledgements

The authors would like to express their gratitude to Gaius Stern, Ph.D., U.C. Berkeley. For English translation support we had on this manuscript.

Author contributions

CP and RVDB conceived study. CP recruited patients and conducted the trial procedures. CP, SQ and RVDB analyzed and interpreted the data. CP, DS, SQ and RVDB drafted the manuscript. LG, CL and AL revised the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest in this work.

Ethical approval

The present study was approved by the ethics committee of the University and adhered to the tenets of the Declaration of Helsinki.

Informed consent

Additionally, the written informed consents were signed by all participants.

References

  1. 1.
    Ballinger A (2002) Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 58(Suppl 1):7–10PubMedGoogle Scholar
  2. 2.
    Wong SC, Dobie R, Altowati MA, Werther GA, Farquharson C, Ahmed SF (2016) Growth and the growth hormone insulin like growth factor 1 axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions. Endocr Rev 37(1):62–110CrossRefGoogle Scholar
  3. 3.
    Poggi M, Pascucci C, Monti S, Pugliese P, Lauri C, Amodeo G, Girelli G, Toscano V (2010) Prevalence of growth hormone deficiency in adult polytransfused β-thalassemia patients and correlation with transfusional and chelation parameters. J Endocrinol Investig 33(8):534–538CrossRefGoogle Scholar
  4. 4.
    Pascucci C et al (2017) Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis. J Endocrinol Investig 41(5):591–596CrossRefGoogle Scholar
  5. 5.
    Bulloch MN et al (2017) Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Expert Rev Clin Pharmacol 10(10):1055–1072CrossRefGoogle Scholar
  6. 6.
    Van Goor F, Yu H, Burton B, Hoffman BJ (2014) Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 13(2014):29–36CrossRefGoogle Scholar
  7. 7.
    Claire E, Wainwright MB et al (2015) Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220–231CrossRefGoogle Scholar
  8. 8.
    Shwachman H, Kulczycki LL (1958) Long term study of one hundred five patients with cystic fibrosis; studies made over a five to fourteen years period. AMA J Dis Child 96(1):6–15CrossRefGoogle Scholar
  9. 9.
    Blackman SM, Tangpricha V (2016) Endocrine disorders in cystic fibrosis. Pediatr Clin N Am 63(4):699–708CrossRefGoogle Scholar
  10. 10.
    Kelly A, Sheikh S, DeLeon D, Camburn D, Peleckis A, Rickels M, Rubenstein RC (2016) B-cell secretory capacity improves in cystic fibrosis with ivacaftor therapy. Pediatr Pulmonol 51(S45):438Google Scholar
  11. 11.
    Tsabari R, Elyashar HI, Cymberknowh MC, Breuer O, Armoni S, Livnat G, Kerem E, Zangen DH (2016) CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J Cyst Fibros 15(3):e25–e27CrossRefGoogle Scholar
  12. 12.
    Yoon JC (2017) Evolving mechanistic views and emerging therapeutic strategies for cystic fibrosis-related diabetes. J Endocr Soc 1(11):1386–1400CrossRefGoogle Scholar
  13. 13.
    Le TN, Schechter MS (2019) Origins of growth deficiencies in cystic fibrosis. Thorax 74(5):423–424CrossRefGoogle Scholar
  14. 14.
    Rogan MP, Reznikov LR, Pezzulo AA et al (2010) Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci USA 07(47):20571–20575CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  • C. Pascucci
    • 1
    Email author
  • R. V. De Biase
    • 2
  • D. Savi
    • 2
    • 3
  • S. Quattrucci
    • 4
  • L. Gnessi
    • 1
  • C. Lubrano
    • 1
  • A. Lenzi
    • 1
  1. 1.Section of Medical Pathophysiology, Endocrinology, Department Experimental MedicineSapienza University of RomeRomeItaly
  2. 2.Cystic Fibrosis UnitBambino Gesù Children’s HospitalRomeItaly
  3. 3.Department of Public Health and Infectious Diseases, Adult Cystic Fibrosis CenterSapienza University of RomeRomeItaly
  4. 4.Pediatrics Department, Cystic Fibrosis Regional CenterSapienza University of RomeRomeItaly

Personalised recommendations